Published online before print June 27, 2005, doi: 10.1161/CIRCULATIONAHA.104.504159
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;112:25-31.)
© 2005 American Heart Association, Inc.
Coronary Heart Disease |
C-Reactive Protein and the 10-Year Incidence of Coronary Heart Disease in Older Men and Women
The Cardiovascular Health Study
From the Departments of Medicine and Pathology (M.C.) and Pathology and Biochemistry (R.P.T.), University of Vermont, Burlington; Departments of Biostatistics (A.M.A.) and Medicine, Epidemiology, and Health Services (B.M.P.), University of Washington, Seattle; Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, Bethesda, Md (T.A.M.); Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pa (L.H.K.); Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC (G.L.B.); and Department of Radiology, Tufts University School of Medicine, Boston, Mass (J.F.P.).
Reprint requests to Mary Cushman, MD, MSc, Department of Medicine, University of Vermont, 208 S Park Dr, Suite 2, Colchester, VT 05446. E-mail mary.cushman{at}uvm.edu
Received September 8, 2004; revision received March 9, 2005; accepted March 25, 2005.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— High C-reactive protein (CRP) is associated with increased coronary heart disease risk. Few long-term data in the elderly are available.
Methods and Results— Baseline CRP was measured in 3971 men and women 
65 years of age without prior vascular diseases; 26% had elevated concentrations (>3 mg/L). With 10 years of follow-up, 547 participants developed coronary heart disease (CHD; defined as myocardial infarction or coronary death). With elevated CRP, the 10-year cumulative CHD incidences were 33% in men and 17% in women. The age-, ethnicity-, and sex-adjusted relative risk of CHD for CRP >3 mg/L compared with <1 mg/L was 1.82 (95% CI, 1.46 to 2.28). Adjusting for conventional risk factors reduced the relative risk to 1.45 (95% CI, 1.14 to 1.86). The population-attributable risk of CHD for elevated CRP was 11%. Risk relationships did not differ in subgroups defined by baseline risk factors. We assessed whether CRP improved prediction by the Framingham Risk Score. Among men with a 10-year Framingham-predicted risk of 10% to 20%, the observed CHD incidence was 32% for elevated CRP. Among women, CRP discriminated best among those with a 10-year predicted risk >20%; the incidences were 31% and 10% for elevated and normal CRP levels, respectively.
Conclusions— In older men and women, elevated CRP was associated with increased 10-year risk of CHD, regardless of the presence or absence of cardiac risk factors. A single CRP measurement provided information beyond conventional risk assessment, especially in intermediate-Framingham-risk men and high-Framingham-risk women.
Key Words: coronary disease • epidemiology • inflammation • myocardial infarction • risk factors
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Older adults are the demographic group at highest risk of myocardial infarction (MI). Although cardiovascular risk factor levels in middle-aged individuals are important in MI prediction, utility of some risk factors such as lipid measures has been questioned among older individuals.1,2 The inflammation marker C-reactive protein (CRP) has been reported as a risk factor for MI in several studies of initially healthy subjects.3 In 4 studies including middle-aged subjects, CRP measurement added to the predictive value of the Framingham Risk Score or lipid determination.4–8 A consensus panel reported possible roles of CRP measurement in primary prevention, suggesting that concentrations of 1 to 3 mg/L indicate intermediate risk, levels >3 mg/L indicate increased risk, and levels >10 mg/L might indicate other inflammatory diseases.3 However, a recent large study reported only a modest association of CRP with future coronary heart disease (CHD), and the investigators questioned these recommendations.9
Long-term prospective studies assessing CRP and MI in elderly men and women are not available. In prospective studies of elderly subjects without baseline coronary disease, CRP was associated with short-term risk of MI or angina in the population assessed here10 and with vascular mortality in 2 other studies11,12 but not with MI in older adults in the Rotterdam Study13 or with acute coronary syndrome in the Health, Aging and Body Composition cohort.14
In several studies, associations of CRP with MI were substantially reduced by adjustment for conventional cardiovascular risk factors.9,15–20 Measures of subclinical atherosclerosis such as carotid intima-media thickness and ankle-brachial index predict future MI, possibly because they reflect the lifetime burden of cardiac risk factors or host response to risk factors.21 Adjustment for subclinical disease might provide more complete adjustment for potential confounding, yielding new information on the independence of the association of CRP with MI.
In this report, we analyzed baseline CRP and 10-year incidence of first MI or CHD death in the Cardiovascular Health Study (CHS), a cohort of men and women 65 years of age. We assessed the recommended clinical cut points for elevated CRP3; independence of CRP associations with CHD from risk factors, including subclinical disease; and associations of CRP with CHD in subgroups defined by baseline risk factors, including subclinical disease and the Framingham Risk Score.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The CHS is an observational study of risk factors for cardiovascular disease in 5888 men and women
65 years of age who were enrolled as 2 cohorts at 4 centers in either 1989 to 1990 or 1992 to 1993. The first cohort consisted of 5201 primarily white participants; the second consisted of 687 blacks. Invited participants were a random sample of Health Care Financing Administration eligibility lists and their household members.22 Exclusion criteria included institutionalization, active cancer treatment, or expectation of moving from the area within 2 years. Participants provided informed consent, and institutional review committees approved the study methods. Interview, lipid determination, and testing for subclinical atherosclerosis were completed at enrollment.22 Subclinical disease was measured by carotid ultrasound, ECG, and ankle-brachial blood pressure index as previously described.21 Previous vascular diagnoses were confirmed by medical record review. In 1997, CRP was measured in stored baseline plasma by immunoassay with a coefficient of variation of 6.2%.23,24
Baseline Definitions
Primary analysis of CHD events categorized CRP as low (<1 mg/L), intermediate (1 to 3 mg/L), or elevated (>3 mg/L) to address the utility of recent guidelines.3 CRP >10 mg/L was assessed in secondary analyses.3 Diabetes was defined using the American Diabetes Association criteria. Hypertension was defined as blood pressure 140/90 mm Hg or self-reported hypertension with the use of antihypertensive drugs. Hyperlipidemia was defined as cholesterol 6.22 mmol/L (240 mg/dL), LDL cholesterol 4.14 mmol/L (160 mg/dL), or use of medications for hyperlipidemia. Cigarette use was categorized as never, former, or current and by number of pack-years. Presence of subclinical vascular disease was defined as any 1 of the following: ankle-brachial index <0.9, internal or common carotid artery wall thickness >80th percentile, carotid stenosis >25%, major ECG abnormalities, or positive response to the Rose questionnaires for angina and claudication.21 Regular aspirin use was defined as use during at least 7 of the previous 14 days or by prescription. Framingham Risk Score was calculated25 and reported as low (<10%), intermediate (10% to 20%), or high (>20%) 10-year predicted risk of CHD.
Subjects Included in Analysis
We excluded 1536 participants with confirmed prebaseline cardiovascular disease (MI, angina, congestive heart failure, stroke, transient ischemic attack, claudication, coronary artery bypass surgery, angioplasty, carotid endarterectomy; 715 women, 821 men). Of the remaining women, 326 using oral postmenopausal hormones were excluded because users have higher CRP concentrations with uncertain clinical consequence.26,27 Fifty-five subjects did not have CRP levels available. Exclusions yielded 3971 participants.
Events Ascertainment
Subjects were followed up every 6 months by alternating field center visits and telephone calls between enrollment and June 30, 2000. Vascular outcomes were ascertained by self-report and review of discharge codes for all hospitalizations. For suspected coronary events, medical records were abstracted and then reviewed and classified by a committee using standardized criteria.28,29 CHD death was defined as the absence of nonatherosclerotic cause of death and 1 or both of the following: chest pain within 72 hours of death or history of chronic ischemic heart disease in the absence of valvular heart disease or nonischemic cardiomyopathy.
Statistical Analysis
The SPSS package was used for analysis with a CHS database updated November 18, 2002. Associations of CRP with risk factors were assessed by tests for trend across categories of CRP through the use of 
2 statistics or ANOVA. When indicated, CRP was log transformed and described by its geometric mean. Incidence rates of CHD by CRP category were calculated separately for men and women and within categories of the Framingham Risk Score. Cox proportional-hazards models were used to compute hazard ratios as estimates of relative risk of CHD with increasing category of CRP with adjustment for age, sex, and race in all participants and in subgroups defined by known risk factors. Censoring occurred at death, last follow-up, or June 30, 2000, whichever occurred first. Differences in findings by sex, race, and presence or absence of vascular risk factors were evaluated formally by adding interaction terms of each for these factors with CRP to the model (P=0.05 indicated significance). To determine whether CRP remained predictive after adjustment for known risk factors, 2 additional levels of adjustment were considered. First, models were additionally adjusted for field center and the risk factors related to CRP or MI: hypertension, diabetes, smoking status, pack-years of smoking, body mass index, waist circumference, total and HDL cholesterol, and regular aspirin use. Second, subclinical atherosclerosis measures were added to the models.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Among 3971 participants, 29% had CRP <1.0 mg/L, 45% had levels of 1 to 3 mg/L, and 26% had elevated values (>3 mg/L). The median CRP was 1.76 mg/L (interquartile range, 0.88 to 3.10 mg/L). Associations of CRP with risk factors and subclinical and clinical cardiovascular disease are shown in Table 1. CRP was higher among women and blacks and with obesity, aspirin use, lower HDL cholesterol, hypertension, diabetes, smoking, and pack-years. CRP was higher with than without subclinical disease, with geometric mean values of 1.64 mg/L without subclinical disease and 1.98 mg/L with subclinical disease (P<0.001).
|
With 10 years of follow-up, there were 547 first MI or CHD deaths (354 nonfatal MI, 41 fatal MI, and 152 CHD deaths). Incidence rates were 22.2 and 12.0 per 1000 person-years in men and women, respectively. Figure 1 shows the cumulative incidence of CHD by gender and baseline CRP. There was little difference between participants with low and intermediate CRP levels, but for those with elevated CRP, the incidence was higher, with a 10-year cumulative incidence of 33% in men and 17% in women. Figure 2 shows the incidence of CHD over the full range of CRP values, demonstrating an increase in risk throughout the range.
|
|
Incidence rates and relative risks of CHD by baseline CRP categories are shown in Table 2. Incidence increased with each higher CRP category. Age, sex, and race-adjusted relative risks of CHD were slightly increased for intermediate CRP and were nearly doubled for CRP >3 mg/L. Adjustment for other risk factors attenuated these relative risks, leaving little association with CHD for CRP 1 to 3 mg/L and a 45% increased risk for CRP >3 mg/L. There was no effect of additional adjustment for baseline statin use. Further adjustment for subclinical disease yielded little attenuation; a 37% increased risk of CHD for elevated CRP remained. When CRP was considered a continuous variable, with adjustment for risk factors, the relative risk associated with a 1-ln-unit-higher baseline CRP was 1.27 (95% CI, 1.12 to 1.44). There were no significant differences in associations by sex or race. The population-attributable risk percentage for elevated CRP was 11%.
|
Table 3 shows the relative risks of incident CHD for CRP >3 mg/L compared with CRP <1 mg/L in subgroups based on the presence or absence of cardiovascular risk factors. Baseline CRP was associated with CHD in all of these groups, including those without subclinical disease and those at low risk by the Framingham Risk Score (P for interaction >0.05 for all). Although the relative risk did not differ by subclinical disease status, among men and women, the presence of elevated CRP together with subclinical disease was associated with a higher incidence of CHD compared with those with lower CRP and no subclinical disease (Figure 3).
|
|
Figure 4 shows the 10-year sex-specific incidence of CHD according to CRP concentration in categories of the Framingham Risk Score. In intermediate- and low-risk women, CRP >3 mg/L added little to risk prediction, whereas in high-risk women, CRP provided additional risk information. Among women with a 10-year predicted risk >20%, for intermediate or elevated CRP, the observed incidences were 28%, and 31%, respectively, compared with only 16% for those with low CRP. In men, CRP provided additional risk information in intermediate- and high-Framingham-risk groups. Among men with a 10-year predicted risk 10% to 20%, those with CRP >3 mg/L had an observed risk of 32%. Among high-Framingham-risk men, this observed risk was 41%.
|
We investigated the utility of CRP >10 mg/L for determining risk of CHD and the impact of hormone replacement therapy among women. Of participants with elevated CRP, 22% were >10 mg/L. Of these 233 participants, 49 (21%) developed CHD during follow-up compared with 498 of 3738 (13.3%) with lower CRP. The age-, sex-, and race-adjusted relative risk of CHD was 2.16 (95% CI, 1.55 to 3.00) for CRP >10 compared with <1 mg/L and 1.78 (95% CI, 1.26 to 2.51) after adjustment for traditional risk factors. Among 326 women excluded from analysis for hormone replacement therapy use, the age-adjusted relative risk of CHD for CRP >3 mg/L was 1.35 (95% CI, 0.42 to 4.32).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In this 10-year prospective study in men and women
65 years of age, CHD risk increased with increasing CRP. When recent clinical guidelines were applied, intermediate CRP concentrations (1 to 3 mg/L) were weakly related to future CHD, and elevated CRP (>3.0 mg/L) was associated with a 1.45-fold increased risk of CHD, with adjustment for other vascular risk factors. There was little further confounding with adjustment for the presence of noninvasively assessed subclinical atherosclerosis. Elevated CRP was associated with CHD in all subgroups defined by conventional cardiac risk factors or subclinical disease. Among men with intermediate and high Framingham Risk Scores, CRP identified those with higher-than-predicted risk. Among women, CRP discriminated risk best among those at high Framingham-predicted risk. The relative risk of CHD for elevated CRP observed here was smaller than in most studies of middle-aged subjects and might seem modest at 1.45. However, event rates were high in this age group, so the attributable risk percent for elevated CRP was high at 11%, even given a modest relative risk.30 Thus, a much higher percentage of subjects with elevated CRP subsequently had events in this study compared with studies of younger subjects.7,8 In a recent report by Danesh et al,9 a similar adjusted relative risk was observed in a large population, but in that case-control study, attributable risk was not estimated. If elevated CRP represents a causal risk factor as suggested by several experimental studies,31 our estimate of attributable risk indicates a hypothesis that correction of elevated CRP could eliminate up to 11% of incident CHD in this age group.
It has been suggested that novel risk factors or atherosclerosis imaging may identify those at intermediate CHD risk who might benefit from aggressive risk factor interventions.32 Along with findings in middle-aged populations,7,8 our data provide evidence that CRP assessment can identify older patients at higher or lower than their predicted risk of coronary events. Our findings with regard to women at low and intermediate risk differ from findings in middle-aged women in which CRP predicted cardiovascular events across the entire range of Framingham Risk Scores.33 Further work is needed to validate our findings in this age group and to determine appropriate values defining elevated CRP in various age and sex groups.
Other studies reported weak or no associations of CRP with subclinical disease measures.34–38 Here, in the absence of clinical disease, CRP was higher among those with any single type of subclinical disease. Moreover, CHD incidence was higher among those with elevated CRP and subclinical disease compared with groups with only 1 or neither of these risk factors. In this cohort, the 10-year stroke risk associated with elevated CRP was larger among those with higher compared with lower carotid intima-media thickness.39 In a short-term study, the risk of MI was higher among those with higher coronary artery calcium scores if CRP was also elevated.40 Taken together, findings from these few studies suggest possible roles for the assessment of both inflammation and subclinical disease. It is also possible that CRP is a marker of subclinical disease, and if better measures of subclinical disease were available, adjustment for subclinical disease would further lessen the association of CRP with CHD.
The CDC/AHA guideline for CRP testing suggest that values >10 mg/L indicate acute inflammation and have uncertain implications for vascular risk prediction.3 In this older population, 6% of subjects had CRP >10 mg/L; when traditional risk factors were accounted for, these subjects had a 1.8-fold increased risk of CHD, a higher risk estimate than for CRP >3.0 mg/L. Our finding agrees with recently reported results in middle-aged women.33 Thus, CRP values >10 mg/L appear to be important in CHD risk prediction.
Limitations of this study merit consideration. The cohort, free-living elderly who were willing to enroll in the study, may not represent the general older population. The observational study design, even with extensive multivariate analysis, cannot prove causal relationships. Competing risks may have diluted associations of CRP with CHD because CRP may be associated with other disease outcomes. In some cases, analysis of subgroups was limited by small sample sizes. Finally, CRP was measured only once at baseline, and it has been suggested that repeated testing for confirmation be considered in those with high values.3
Strengths of this study include its large size, extensive baseline data collection, and long-term event follow-up. Several new findings were observed on the basis of unique aspects of the study. First, we confirmed an association of elevated CRP with CHD incidence in an older age group; most previous studies included younger subjects or clinical trial participants. Second, independence of associations from noninvasively measured subclinical atherosclerosis was documented. Third, more complete adjustment for smoking status was made by assessing pack-years, a major determinant of CRP concentration in smokers.34 Fourth, because CRP was measured in the whole cohort, incidence rates of CHD by baseline CRP were calculated, and subgroup analyses could be done.
In conclusion, we extend previous reports on the association of CRP with CHD to men and women 65 years of age. CRP appears to be useful for risk assessment in this age group. Because event rates are high overall in older age, further study is required to determine optimal clinical roles of CRP measurement, especially as related to interventions for elevated CRP.
|
Acknowledgments |
|---|
This research was supported by contracts N01-HC-85079 through N01-HC-85086, N01-HC-35129, and N01-HC-15103 and grants HL-46696, HL-8329, and HL-03618 from the NIH National Heart, Lung and Blood Institute. A full list of participating CHS investigators and institutions can be found at http://www.chs-nhlbi.org.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Psaty BM, Furberg CD, Kuller LH, Bild DE, Rautaharju PM, Polak JF, Bovill E, Gottdiener JS. Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults: the Cardiovascular Health Study. Arch Intern Med. 1999; 159: 1339–1347.
2. Psaty BM, Anderson M, Kronmal RA, Tracy RP, Orchard T, Fried LF, Lumley T, Robbins J, Burke G, Newman AB, Furberg CD. The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: the Cardiovascular Health Study. Am J Geriatr Soc. 2004; 52: 1639–1647.[CrossRef][Medline] [Order article via Infotrieve]
3. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and Public Health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107: 499–511.
4. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998; 97: 2007–2011.
5. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342: 836–843.
6. Kervinen H, Palosuo T, Manninen V, Tenkanen L, Vaarala O, Manttari M. Joint effects of C-reactive protein and other risk factors on acute coronary events. Am Heart J. 2001; 141: 580–585.[CrossRef][Medline] [Order article via Infotrieve]
7. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347: 1557–1565.
8. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004; 109: 1349–1353.
9. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004; 350: 1387–1397.
10. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilhan EN, Kuller LH. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997; 17: 1121–1127.
11. Harris TB, Ferruci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH, Heimovitz H, Cohen HJ, Wallace R. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999; 106: 506–512.[CrossRef][Medline] [Order article via Infotrieve]
12. Tice JA, Browner W, Tracy RP, Cummings SR. The relation of C-reactive protein levels to total and cardiovascular mortality in older U.S. women. Am J Med. 2003; 114: 199–205.[CrossRef][Medline] [Order article via Infotrieve]
13. van der Meer IM, de Maat MP, Kiliaan AJ, van der Kuip DA, Hofman A, Witteman JC. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med. 2003; 163: 1323–1328.
14. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M. Inflammatory markers and onset of cardiovascular events: results from the Health ABC Study. Circulation. 2003; 108: 2317–2322.
15. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol. 1999; 19: 3071–3078.
16. Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM, Elwood PC. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J. 2000; 21: 1584–1590.
17. Doggen CJM, Berckmans RJ, Sturk A, Manger Cats V, Rosendaal FR. C-reactive protein, cardiovascular risk factors and the association with myocardial infarction in men. J Intern Med. 2000; 248: 406–414.[CrossRef][Medline] [Order article via Infotrieve]
18. Gram J, Bladbjerg EM, Moller L, Sjol A, Jespersen J. Tissue-type plasminogen activator and C-reactive protein in acute coronary heart disease a nested case-control study. J Intern Med. 2000; 247: 205–212.[CrossRef][Medline] [Order article via Infotrieve]
19. Packard CJ, O’Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease: West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000; 343: 1148–1155.
20. Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu KK. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2002; 144: 233–238.[CrossRef][Medline] [Order article via Infotrieve]
21. Kuller LH, Shemanski L, Psaty BM, Borhani NO, Gardin J, Haan MN, O’Leary DH, Savage PJ, Tell GS, Tracy R. Subclinical disease as an independent risk factor for cardiovascular disease. Circulation. 1995; 92: 720–726.
22. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, O’Leary DH, Psaty B, Rautaharju P, Tracy RP, Weiler PG, CHS Research Group. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991; 1: 263–276.[Medline] [Order article via Infotrieve]
23. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem. 1997; 43: 52–58.
24. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999; 45: 2136–2141.
25. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97: 1837–1847.
26. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Circulation. 1999; 100: 717–722.
27. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger MB, Ridker PM. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women’s Health Initiative observational study. JAMA. 2002; 288: 980–987.
28. Price TR, Psaty BM, O’Leary DH, Burke G, Gardin J, for the Cardiovascular Health Study Research Group. Assessment of cerebrovascular disease in the Cardiovascular Health Study. Ann Epidemiol. 1993; 3: 504–507.[Medline] [Order article via Infotrieve]
29. Ives DG, Fitzpatrick AL, Bild DE, Psaty BM, Kuller LH, Crowley PM, Cruise RG, Theroux S. Surveillance and ascertainment of cardiovascular events: the Cardiovascular Health Study. Ann Epidemiol. 1995; 5: 278–285.[CrossRef][Medline] [Order article via Infotrieve]
30. Psaty BM, Koepsell TD, Manolio TA, Longstreth WT Jr, Wagner EH, Wahl PW, Kronmal RA. Risk ratios and risk differences in estimating the effect of risk factors for cardiovascular disease in the elderly. J Clin Epidemiol. 1990; 43: 961–970.[CrossRef][Medline] [Order article via Infotrieve]
31. Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM. 2003; 96: 793–807.
32. Greenland P, Smith SC Jr, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation. 2001; 104: 1863–1867.
33. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation. 2004; 109: 1955–1959.
34. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, Kuller LH. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 1997; 17: 2167–2176.
35. Redberg RF, Rifai N, Gee L, Ridker PM. Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening. J Am Coll Cardiol. 2000; 36: 39–43.
36. Folsom AR, Pankow JS, Tracy RP, Arnett DK, Peacock JM, Hong Y, Djousse L, Eckfeldt JH. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol. 2001; 88: 112–117.[CrossRef][Medline] [Order article via Infotrieve]
37. Blackburn R, Giral P, Bruckert E, Andre JM, Gonbert S, Bernard M, Chapman MJ, Turpin G. Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects. Arterioscler Thromb Vasc Biol. 2001; 21: 1962–1968.
38. Wang TJ, Nam BH, Wilson PW, Wolf PA, Levy D, Polak JF, D’Agostino RB, O’Donnell CJ. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2002; 22: 1662–1667.
39. Cao JJ, Thach C, Manolio TA, Psaty BM, Kuller LH, Chaves PH, Polak JF, Sutton-Tyrrell K, Herrington DM, Price TR, Cushman M. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation. 2003; 108: 166–170.
40. Park R, Detrano R, Xiang M, Fu P, Ibrahim Y, LaBree L, Azen S. Combined use of computed tomography coronary calcium scores and C-reactive protein levels in predicting cardiovascular events in nondiabetic individuals. Circulation. 2002; 106: 2073–2077.
This article has been cited by other articles:
 |
|
 |
|
  I. Tzoulaki, G. Liberopoulos, and J. P. A. Ioannidis Assessment of Claims of Improved Prediction Beyond the Framingham Risk Score JAMA, December 2, 2009; 302(21): 2345 - 2352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. I. Buckley, R. Fu, M. Freeman, K. Rogers, and M. Helfand C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-analyses for the U.S. Preventive Services Task Force Ann Intern Med, October 6, 2009; 151(7): 483 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Helfand, D. I. Buckley, M. Freeman, R. Fu, K. Rogers, C. Fleming, and L. L. Humphrey Emerging Risk Factors for Coronary Heart Disease: A Summary of Systematic Reviews Conducted for the U.S. Preventive Services Task Force Ann Intern Med, October 6, 2009; 151(7): 496 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Bernstein, D. Damron, A. L. Schonberg, and R. Shapiro The Relationship of Plasma Volume, Sympathetic Tone, and Proinflammatory Cytokines in Young Healthy Nonpregnant Women Reproductive Sciences, October 1, 2009; 16(10): 980 - 985. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Keller, R. Katz, M. J. Sarnak, L. F. Fried, B. Kestenbaum, M. Cushman, M. G. Shlipak, and for the CHS study Inflammatory biomarkers and decline in kidney function in the elderly: the Cardiovascular Health Study Nephrol. Dial. Transplant., September 3, 2009; (2009) gfp429v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cushman, L. A. McClure, V. J. Howard, N. S. Jenny, S. G. Lakoski, and G. Howard Implications of Increased C-Reactive Protein for Cardiovascular Risk Stratification in Black and White Men and Women in the US Clin. Chem., September 1, 2009; 55(9): 1627 - 1636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Elliott, J. C. Chambers, W. Zhang, R. Clarke, J. C. Hopewell, J. F. Peden, J. Erdmann, P. Braund, J. C. Engert, D. Bennett, et al. Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease JAMA, July 1, 2009; 302(1): 37 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sabate and Y. Ang Nuts and health outcomes: new epidemiologic evidence Am. J. Clinical Nutrition, May 1, 2009; 89(5): 1643S - 1648S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease Clin. Chem., February 1, 2009; 55(2): 209 - 215. [Full Text] [PDF]
|
|
|
|
|
|
A. D. Hingorani, T. Shah, J. P. Casas, S. E. Humphries, and P. J. Talmud C-Reactive Protein and Coronary Heart Disease: Predictive Test or Therapeutic Target? Clin. Chem., February 1, 2009; 55(2): 239 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. SHISHEHBOR and S. L. HAZEN JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean? Cleveland Clinic Journal of Medicine, January 1, 2009; 76(1): 37 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Poole, P. Conway, and C. J. Currie An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immune-mediated inflammatory disease managed in UK general practice Rheumatology, January 1, 2009; 48(1): 78 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Esmaillzadeh and L. Azadbakht Home use of vegetable oils, markers of systemic inflammation, and endothelial dysfunction among women Am. J. Clinical Nutrition, October 1, 2008; 88(4): 913 - 921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Surtees, N. W. J. Wainwright, S. M. Boekholdt, R. N. Luben, N. J. Wareham, and K.-T. Khaw Major Depression, C-Reactive Protein, and Incident Ischemic Heart Disease in Healthy Men and Women Psychosom Med, October 1, 2008; 70(8): 850 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Ankle Brachial Index Collaboration Ankle Brachial Index Combined With Framingham Risk Score to Predict Cardiovascular Events and Mortality: A Meta-analysis JAMA, July 9, 2008; 300(2): 197 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Tabassum, M. Kumari, A. Rumley, G. Lowe, C. Power, and D. P. Strachan Effects of Socioeconomic Position on Inflammatory and Hemostatic Markers: A Life-Course Analysis in the 1958 British Birth Cohort Am. J. Epidemiol., June 1, 2008; 167(11): 1332 - 1341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B Panagiotakos, C. Pitsavos, C. Chrysohoou, I. Skoumas, and C. Stefanadis Five-year incidence of cardiovascular disease and its predictors in Greece: the ATTICA study Vascular Medicine, May 1, 2008; 13(2): 113 - 121. [Abstract] [PDF]
|
|
|
|
 |
|
 C J Currie, C D Poole, and P Conway Evaluation of the association between the first observation and the longitudinal change in C-reactive protein, and all-cause mortality Heart, April 1, 2008; 94(4): 457 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Clarke, J. R. Emberson, E. Breeze, J. P. Casas, S. Parish, A. D. Hingorani, A. Fletcher, R. Collins, and L. Smeeth Biomarkers of inflammation predict both vascular and non-vascular mortality in older men Eur. Heart J., March 2, 2008; 29(6): 800 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Haugen, I. P. Casserly, J. G. Regensteiner, and W. R. Hiatt Risk assessment in the patient with established peripheral arterial disease Vascular Medicine, November 1, 2007; 12(4): 343 - 350. [Abstract] [PDF]
|
|
|
|
 |
|
 M Rosvall, G Engstrom, L Janzon, G Berglund, and B Hedblad The role of low grade inflammation as measured by C-reactive protein levels in the explanation of socioeconomic differences in carotid atherosclerosis Eur J Public Health, August 1, 2007; 17(4): 340 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Ridker C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk: Moving an Inflammatory Hypothesis Toward Consensus J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2129 - 2138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Lange, E. M. Lange, R. P. Tracy, and A. P. Reine Polymorphisms in the CRP Gene and Cardiovascular Events--Reply JAMA, March 28, 2007; 297(12): 1317 - 1318. [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Revkin, C. L. Shear, H. G. Pouleur, S. W. Ryder, and D. G. Orloff Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future Pharmacol. Rev., March 1, 2007; 59(1): 40 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sattar, H. M. Murray, A. McConnachie, G. J. Blauw, E. L.E.M. Bollen, B. M. Buckley, S. M. Cobbe, I. Ford, A. Gaw, M. Hyland, et al. C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Circulation, February 27, 2007; 115(8): 981 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Koenig and N. Khuseyinova Biomarkers of Atherosclerotic Plaque Instability and Rupture Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 15 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Wang, P. Gona, M. G. Larson, G. H. Tofler, D. Levy, C. Newton-Cheh, P. F. Jacques, N. Rifai, J. Selhub, S. J. Robins, et al. Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death N. Engl. J. Med., December 21, 2006; 355(25): 2631 - 2639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Lange, C. S. Carlson, L. A. Hindorff, E. M. Lange, J. Walston, J. P. Durda, M. Cushman, J. C. Bis, D. Zeng, D. Lin, et al. Association of Polymorphisms in the CRP Gene With Circulating C-Reactive Protein Levels and Cardiovascular Events JAMA, December 13, 2006; 296(22): 2703 - 2711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Howard-Alpe, J. W. Sear, and P. Foex Methods of detecting atherosclerosis in non-cardiac surgical patients; the role of biochemical markers Br. J. Anaesth., December 1, 2006; 97(6): 758 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Libby and P. M. Ridker Inflammation and Atherothrombosis: From Population Biology and Bench Research to Clinical Practice J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A33 - A46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Marsik, R. Sunder-Plassmann, B. Jilma, F. M. Kovar, C. Mannhalter, O. Wagner, H. Rumpold, and G. Endler The C-Reactive Protein +1444C/T Alteration Modulates the Inflammation and Coagulation Response in Human Endotoxemia Clin. Chem., October 1, 2006; 52(10): 1952 - 1957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Albert and P. M Ridker C-Reactive Protein as a Risk Predictor: Do Race/Ethnicity and Gender Make a Difference? Circulation, August 1, 2006; 114(5): e67 - e74. [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Folsom, L. E. Chambless, C. M. Ballantyne, J. Coresh, G. Heiss, K. K. Wu, E. Boerwinkle, T. H. Mosley Jr, P. Sorlie, G. Diao, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med, July 10, 2006; 166(13): 1368 - 1373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Cook, J. E. Buring, and P. M Ridker The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women Ann Intern Med, July 4, 2006; 145(1): 21 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M Ridker, E. Danielson, N. Rifai, R. J. Glynn, and for the Val-MARC Investigators Valsartan, Blood Pressure Reduction, and C-Reactive Protein: Primary Report of the Val-MARC Trial Hypertension, July 1, 2006; 48(1): 73 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Scirica, D. A. Morrow, S. Verma, S. Devaraj, I. Jialal, B. M. Scirica, D. A. Morrow, S. Verma, S. Devaraj, and I. Jialal The Verdict Is Still Out Circulation, May 2, 2006; 113(17): 2128 - 2151. [Full Text] [PDF]
|
|
|
|
|
|
S. Tsimikas, J. T. Willerson, and P. M. Ridker C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J. Am. Coll. Cardiol., April 18, 2006; 47(8 Suppl): C19 - C31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. O'Hare, R. Katz, M. G. Shlipak, M. Cushman, and A. B. Newman Mortality and Cardiovascular Risk Across the Ankle-Arm Index Spectrum: Results From the Cardiovascular Health Study Circulation, January 24, 2006; 113(3): 388 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Dickstein C-reactive protein in ischaemic cardiomyopathy: assessing vascular risk in heart failure Eur. Heart J., November 1, 2005; 26(21): 2218 - 2219. [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Clearfield C-Reactive Protein: A New Risk Assessment Tool for Cardiovascular Disease J Am Osteopath Assoc, September 1, 2005; 105(9): 409 - 416. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||